Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New obesity drug VK2735 enters final testing phase

NCT ID NCT07104500

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests an experimental drug called VK2735, given as a weekly injection, to help people with obesity or overweight lose weight. About 4500 adults without diabetes will receive either the drug or a placebo for 78 weeks. The main goal is to see how much weight they lose and if the drug is safe.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

About 4,500 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2025

Expected to finish

Aug 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age ≥18 years of age at the time of signing the informed consent 2. Body mass index (BMI) ≥30 kg/m2 OR ≥27 kg/m2 with at least one weight-related co- morbid condition (treated or untreated) * Weight-related co-morbid conditions include hypertension, dyslipidemia, obstructive sleep apnea or cardiovascular disease * Cardiovascular disease includes, for example, ischemic cardiovascular disease, New York Heart Association (NYHA) Functional Class I-III heart failure * BMI calculated at the Screening visit will be used to determine eligibility Exclusion Criteria: 1. History of or current clinically significant medical disorder that, in the opinion of the Investigator, does not support study participation 2. Self-reported body weight change of 5% or more within 3 months of screening 3. Have a prior or planned surgical treatment for obesity (excluding liposuction or abdominoplasty if performed \>1 year prior to screening) 4. Have or plan to have endoscopic and/or device-based therapy for obesity or have had device removal within the last 6 months prior to screening (such as, mucosa ablation, gastric artery embolization, intragastric balloon, duodenal-jejunal endoluminal line) 5. Current or past diagnosis of diabetes mellitus (including type 1, type 2, except gestational diabetes) 6. Treatment with glucose-lowering agent(s) within 90 days before screening 7. Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2) 8. History of acute or chronic pancreatitis

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Obesity are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

obesity disorder Weight Loss

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Viking Clinical Site #1001

    Methuen, Massachusetts, 01844, United States

  • Viking Clinical Site #1002

    Ogden, Utah, 84405, United States

  • Viking Clinical Site #1003

    Cooper City, Florida, 33024, United States

  • Viking Clinical Site #1004

    Knoxville, Tennessee, 37909, United States

  • Viking Clinical Site #1005

    Chandler, Arizona, 85210, United States

  • Viking Clinical Site #1006

    Chicago, Illinois, 60607, United States

  • Viking Clinical Site #1007

    Austin, Texas, 78705, United States

  • Viking Clinical Site #1008

    Nashville, Tennessee, 37203, United States

  • Viking Clinical Site #1009

    Louisville, Kentucky, 40213, United States

  • Viking Clinical Site #1010

    Butte, Montana, 59701, United States

  • Viking Clinical Site #1011

    Port Orange, Florida, 32127, United States

  • Viking Clinical Site #1012

    Ocoee, Florida, 34761, United States

  • Viking Clinical Site #1013

    Clearwater, Florida, 33756, United States

  • Viking Clinical Site #1014

    Lake Forest, California, 92630, United States

  • Viking Clinical Site #1016

    Kansas City, Missouri, 64131, United States

  • Viking Clinical Site #1017

    Flagstaff, Arizona, 86001, United States

  • Viking Clinical Site #1018

    Peoria, Arizona, 85381, United States

  • Viking Clinical Site #1019

    Tucson, Arizona, 85711, United States

  • Viking Clinical Site #1020

    Metairie, Louisiana, 70006, United States

  • Viking Clinical Site #1021

    The Bronx, New York, 10455, United States

  • Viking Clinical Site #1022

    West Des Moines, Iowa, 50266, United States

  • Viking Clinical Site #1023

    North Charleston, South Carolina, 29405, United States

  • Viking Clinical Site #1024

    St. George, Utah, 84790, United States

  • Viking Clinical Site #1025

    Woodstock, Georgia, 30189, United States

  • Viking Clinical Site #1026

    Greensboro, North Carolina, 27410, United States

  • Viking Clinical Site #1027

    Fargo, North Dakota, 58104, United States

  • Viking Clinical Site #1028

    Greenville, South Carolina, 29607, United States

  • Viking Clinical Site #1029

    Albuquerque, New Mexico, 87109, United States

  • Viking Clinical Site #1030

    Columbus, Georgia, 31904, United States

  • Viking Clinical Site #1031

    City of Saint Peters, Missouri, 63303, United States

  • Viking Clinical Site #1032

    Westfield, New York, 14787, United States

  • Viking Clinical Site #1034

    Reno, Nevada, 89511, United States

  • Viking Clinical Site #1035

    Las Vegas, Nevada, 89148, United States

  • Viking Clinical Site #1036

    Little Rock, Arkansas, 72211, United States

  • Viking Clinical Site #1037

    Birmingham, Alabama, 35235, United States

  • Viking Clinical Site #1038

    Ypsilanti, Michigan, 48197, United States

  • Viking Clinical Site #1039

    Sandy City, Utah, 84094, United States

  • Viking Clinical Site #1040

    Lexington, Kentucky, 40513, United States

  • Viking Clinical Site #1041

    Spokane, Washington, 99218, United States

  • Viking Clinical Site #1042

    East Syracuse, New York, 13057, United States

  • Viking Clinical Site #1043

    Cincinnati, Ohio, 45219, United States

  • Viking Clinical Site #1044

    Cleveland, Ohio, 44122, United States

  • Viking Clinical Site #1045

    East Greenwich, Rhode Island, 02818, United States

  • Viking Clinical Site #1046

    Houston, Texas, 77040, United States

  • Viking Clinical Site #1047

    Abilene, Texas, 79606, United States

  • Viking Clinical Site #1048

    Dallas, Texas, 75235, United States

  • Viking Clinical Site #1049

    Dallas, Texas, 75230, United States

  • Viking Clinical Site #1050

    Long Beach, California, 90815, United States

  • Viking Clinical Site #1051

    Lincoln, California, 95648, United States

  • Viking Clinical Site #1052

    Spring Valley, California, 91978, United States

  • Viking Clinical Site #1053

    Montclair, California, 91763, United States

  • Viking Clinical Site #1054

    Huntington Park, California, 90255, United States

  • Viking Clinical Site #1055

    Los Angeles, California, 90057, United States

  • Viking Clinical Site #1056

    Palmetto Bay, Florida, 33157, United States

  • Viking Clinical Site #1057

    West Palm Beach, Florida, 33407, United States

  • Viking Clinical Site #1058

    Jacksonville, Florida, 32216, United States

  • Viking Clinical Site #1059

    New Port Richey, Florida, 34652, United States

  • Viking Clinical Site #1060

    Lakewood Rch, Florida, 34211, United States

  • Viking Clinical Site #1061

    Morehead City, North Carolina, 28857, United States

  • Viking Clinical Site #1062

    Honolulu, Hawaii, 96814, United States

  • Viking Clinical Site #1063

    Austin, Texas, 78131, United States

  • Viking Clinical Site #1064

    Birmingham, Alabama, 35249, United States

  • Viking Clinical Site #1065

    Lebanon, New Hampshire, 03756, United States

  • Viking Clinical Site #1066

    Rockville, Maryland, 20854, United States

  • Viking Clinical Site #1067

    Van Nuys, California, 91405, United States

  • Viking Clinical Site #1068

    Panorama City, California, 91402, United States

  • Viking Clinical Site #1069

    Lexington, Kentucky, 40509, United States

  • Viking Clinical Site #1070

    Escondido, California, 92025, United States

  • Viking Clinical Site #1071

    Chula Vista, California, 91911, United States

  • Viking Clinical Site #1072

    Renton, Washington, 98057, United States

  • Viking Clinical Site #1073

    San Antonio, Texas, 78229, United States

  • Viking Clinical Site #1074

    Cincinnati, Ohio, 45242, United States

  • Viking Clinical Site #1075

    Omaha, Nebraska, 68134, United States

  • Viking Clinical Site #1076

    Lakeland, Florida, 33803, United States

  • Viking Clinical Site #1077

    Lampasas, Texas, 76550, United States

  • Viking Clinical Site #1078

    Manteca, California, 95336, United States

  • Viking Clinical Site #1079

    Walnut Creek, California, 94598, United States

  • Viking Clinical Site #1080

    Meridian, Idaho, 83642, United States

  • Viking Clinical Site #1081

    Mobile, Alabama, 36608, United States

  • Viking Clinical Site #1082

    Suffolk, Virginia, 23435, United States

  • Viking Clinical Site #1083

    Fort Myers, Florida, 33912, United States

  • Viking Clinical Site #1085

    San Antonio, Texas, 78222, United States

  • Viking Clinical Site #1086

    San Juan, 00927, Puerto Rico

  • Viking Clinical Site #1087

    Monroe, Louisiana, 71201, United States

  • Viking Clinical Site #1088

    Albany, New York, 12205, United States

  • Viking Clinical Site #1089

    Columbus, Ohio, 43215, United States

  • Viking Clinical Site #1090

    Chicago, Illinois, 60640, United States

  • Viking Clinical Site #1091

    Bellaire, Texas, 77401, United States

  • Viking Clinical Site #1092

    Salt Lake City, Utah, 84107, United States

  • Viking Clinical Site #1093

    Savannah, Georgia, 31406, United States

  • Viking Clinical Site #1094

    Chevy Chase, Maryland, 20815, United States

  • Viking Clinical Site #1095

    Marlton, New Jersey, 08009, United States

  • Viking Clinical Site #1096

    Hartsdale, New York, 10530, United States

  • Viking Clinical Site #1097

    Portland, Oregon, 97202, United States

  • Viking Clinical Site #1098

    Arlington, Virginia, 22205, United States

  • Viking Clinical Site #1099

    Wichita, Kansas, 67207, United States

  • Viking Clinical Site #1101

    Waco, Texas, 76710, United States

  • Viking Clinical Site #1102

    Medford, Oregon, 97504, United States

  • Viking Clinical Site #1103

    Boston, Massachusetts, 02114, United States

  • Viking Clinical Site #1104

    Santa Maria, California, 93458, United States

  • Viking Clinical Site #1106

    Lafayette, Louisiana, 70508, United States

  • Viking Clinical Site #1107

    Delray Beach, Florida, 33445, United States

  • Viking Clinical Site #1108

    St Louis, Missouri, 63108, United States

  • Viking Clinical Site #1109

    Tustin, California, 92780, United States

  • Viking Clinical Site #1110

    Morehead City, North Carolina, 28557, United States

  • Viking Clinical Site #1111

    Frisco, Texas, 75033, United States

  • Viking Clinical Site #1112

    DeLand, Florida, 32720, United States

  • Viking Clinical Site #1113

    Norman, Oklahoma, 73069, United States

  • Viking Clinical Site #1116

    Atlanta, Georgia, 30329, United States

  • Viking Clinical Site #1117

    Miami, Florida, 33122, United States

  • Viking Clinical Site #1118

    Baton Rouge, Louisiana, 70808, United States

  • Viking Clinical Site #1119

    Denver, Colorado, 80210, United States

  • Viking Clinical Site #1120

    Rincon, Georgia, 31326, United States

  • Viking Clinical Site #1121

    Clearwater, Florida, 33761, United States

  • Viking Clinical Site #1122

    Durham, North Carolina, 27701, United States

  • Viking Clinical Site #1123

    Washington D.C., District of Columbia, 20036, United States

  • Viking Clinical Site #1124

    Brownsville, Texas, 78526, United States

  • Viking Clinical Site #1125

    Springfield, Missouri, 65807, United States

  • Viking Clinical Site #1126

    Portland, Oregon, 97210, United States

  • Viking Clinical Site #1127

    Valparaiso, Indiana, 46383, United States

  • Viking Clinical Site #1128

    Huntsville, Alabama, 35801, United States

  • Viking Clinical Site #1129

    Lemon Grove, California, 91945, United States

  • Viking Clinical Site #1130

    Mayagüez, 00680, Puerto Rico

  • Viking Clinical Site #1131

    San Diego, California, 92103, United States

  • Viking Clinical Site #1132

    Rolling Hills Estates, California, 90274, United States

  • Viking Clinical Site #1133

    New York, New York, 10036, United States

  • Viking Clinical Site #1134

    Myrtle Beach, South Carolina, 29572, United States

  • Viking Clinical Site #1135

    Scottsdale, Arizona, 85260, United States

  • Viking Clinical Site #1136

    Needham, Massachusetts, 02492, United States

  • Viking Clinical Site #1137

    Tulsa, Oklahoma, 74133, United States

  • Viking Clinical Site #1138

    Westmont, Illinois, 60559, United States

  • Viking Clinical Site #1139

    Baton Rouge, Louisiana, 70809, United States

  • Viking Clinical Site #1140

    Gulfport, Mississippi, 39503, United States

  • Viking Clinical Site #1141

    Charlotte, North Carolina, 28250, United States

  • Viking Clinical Site #1142

    New York, New York, 10065, United States

  • Viking Clinical Site #1143

    San Antonio, Texas, 78215, United States

  • Viking Clinical Site #1144

    Fayetteville, North Carolina, 28304, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.